VANI (Vivani Medical) EBIT: $-27.23 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VANI Vivani Medical Inc VANI
33 GF Score
Price $1.32
! 1 Warning Sign
View Full Analysis

What is Vivani Medical EBIT?

Vivani Medical VANI -2.59% 33 EBIT is $-27.23 Mil as of Jun. 2026. GuruFocus rates VANI with a GF Score™ of 33/100. The stock has 1 warning sign investors should review.

Vivani Medical's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2026 was $-6.87 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2026 was $-27.23 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Vivani Medical's annualized ROC % for the quarter that ended in Jun. 2026 was -121.93%. Vivani Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was -143.26%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Vivani Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was -23.35%.

Vivani Medical  (NAS:VANI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Vivani Medical's annualized ROC % for the quarter that ended in Jun. 2026 is calculated as:

ROC % (Q: Jun. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2026 ) + Invested Capital (Q: Jun. 2026 ))/ count )
=-27.496 * ( 1 - 0% )/( (22.936 + 22.164)/ 2 )
=-27.496/22.55
=-121.93 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=42.353 - 4.644 - ( 19.749 - max(0, 6.775 - 21.548+19.749))
=22.936

Invested Capital(Q: Jun. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=41.639 - 4.499 - ( 19.894 - max(0, 6.659 - 21.635+19.894))
=22.164

Note: The Operating Income data used here is four times the quarterly (Jun. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Vivani Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2026  Q: Jun. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-27.496/( ( (19.368 + max(-3.879, 0)) + (19.019 + max(-3.784, 0)) )/ 2 )
=-27.496/( ( 19.368 + 19.019 )/ 2 )
=-27.496/19.1935
=-143.26 %

where Working Capital is:

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.012 + 0 + 1.102) - (4.644 + 0 + 0.349)
=-3.879

Working Capital(Q: Jun. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.032) - (4.499 + 0 + 0.317)
=-3.784

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Vivani Medical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2026 )
=-27.226/116.580
=-23.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivani Medical EBIT Related Terms

Vivani Medical EBIT Historical Data

* Premium members only.

The historical data trend for Vivani Medical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivani Medical EBIT Chart

Vivani Medical Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial -13.32 -21.24 -26.97 -24.68 -27.56

Vivani Medical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.46 -6.73 -6.81 -6.82 -6.87

VANI vs BDTX, VTVT, TLSA: EBIT Comparison

For the Biotechnology subindustry, Vivani Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vivani Medical EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vivani Medical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Vivani Medical's EV-to-EBIT falls into.


VANI
33GF Score
Vivani Medical Inc VANI
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivani Medical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-27.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-27.23 Mil mean?
Vivani Medical (VANI) has a EBIT of $-27.23 Mil as of Jun. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Vivani Medical.
Is Vivani Medical's EBIT too high?
Vivani Medical's current EBIT is $-27.23 Mil. Overall, Vivani Medical has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Vivani Medical's EBIT compare to BDTX and VTVT?
Vivani Medical's EBIT of $-27.23 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Vivani Medical. Vivani Medical's current EBIT is $-27.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivani Medical stock overvalued right now?
Vivani Medical (VANI) has a current EBIT of $-27.23 Mil. The current EBIT is $-27.23 Mil. Vivani Medical's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Vivani Medical (VANI), the current EBIT is $-27.23 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vivani Medical Business Description

Other Exchanges U5P:Germany
Address 1350 South Loop Road, Alameda, CA, USA, 94502
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.
33GF Score

Get the complete analysis for VANI

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.32
Price